<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959621</url>
  </required_header>
  <id_info>
    <org_study_id>HABENOX</org_study_id>
    <nct_id>NCT00959621</nct_id>
  </id_info>
  <brief_title>Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion</brief_title>
  <acronym>HABENOX</acronym>
  <official_title>Role of LMWH (Enoxaparine) With or Without Aspirin in the Prevention of Habitual Abortion; Special Attention to the Thrombophilic Status of the Mother</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden Hospital, Leiden, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1 % of all pregnancies end in habitual/recurrent abortion. In about half of women with
      habitual abortions (HAB) hereditary or acquired (antiphospholipid antibodies) thrombophilia
      are observed. The investigators wanted to test whether antithrombotic treatment
      (Low-Molecular Weight Heparin, LMWH, ASA or both combined)would prevent these women from a
      subsequent abortion. Depending on thrombophilic status the women included in one of the three
      sub-studies: HABENOX 1 (mild, single thrombophilia), HABENOX 2 (no known thrombophilia),
      HABENOX 3 (moderate to severe thrombophilia, with combined thrombophilia or moderate to high
      titer antiphospholipid antibodies).

      Study design: Randomised placebo controlled multicenter study.

      Number of patients per study: 90 patients per group, 270 altogether.

      Timetable: Starting 2/2002, finishing 31.12.2007.

      Time frame: &gt;37 weeks of gestation and &gt;24, but &lt;37 weeks of gestation (premature)

      Treatment started before 7. gw.

      HABENOX 1 and 2:

      Study groups:

      Group 1 : Enoxaparin 40 mg+ placebo, Group 2: Enoxaparin 40 +ASA 100 mg, Group 3: ASA.

      HABENOX 3:

      Study groups:

      Group 1: Enoxaparin 40 twice daily+ placebo o.d., Group 2: Enoxaparin 40 mg twice daily +ASA
      100 mg o.d.

      Primary end-points:

      Pregnancy outcome: livebirths ( ≥37 weeks of gestation), premature livebirths (≥24, but &lt;37
      weeks of gestation)

      Secondary end-points: Bleeding complications, intrauterine growth retardation (&lt;-2SD),
      pre-eclampsia, abruptio placentae,

      Ending: In the group of combined medication, tablets will be stopped at 36 weeks of
      gesta-tion. LMWH will be started in all patients after delivery and continued 6 weeks
      postpartum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The prevalence of spontaneous abortions is 1000-1500/10000 pregnancies per year
      meaning that 10-15% of all pregnancies will end in an abortion; 1/10 of these abortions are
      recurrent (1 % of all pregnancies). In about half of women with habitual abortions (HAB)
      hereditary (F V Leiden, F II (prothrombin) mutation, Protein C, S deficiency and
      anti-thrombin) or acquired (antiphospholipid antibodies) thrombophilia are observed. Efficacy
      of the medical treatment of patients with a history of HAB has yet to be completely
      demonstrated. We have recently shown that low-molecular-weight heparin (LMWH) is as effective
      as unfractionated heparin in prevention of thromboembolic complications in pregnant women and
      causes less bleeding complications (UFH) and has no osteoporotic effect. LMWH could be safer
      than UF-heparin during long treatment periods (7-8 months).

      Study design: Randomised placebo controlled multicenter study.

      Centers: Helsinki (2), Oulu (1), Stockholm (1), Leiden (1)

      Number of patients per study: 90 patients per group, 270 altogether

      Timetable: Starting 2/2002, finishing 31.12.2007

      Drugs:

      HABENOX 1 and 2: Study groups Group 1 : Enoxaparin 40 mg+ placebo, Group 2: Enoxaparin 40
      +ASA 100 mg, Group 3: ASA.

      HABENOX 3: Study groups Group 1: Enoxaparin 40 twice daily+ placebo o.d., Group 2: Enoxaparin
      40 mg twice daily +ASA 100 mg o.d.

      Time frame: one year since entering the study with primary end-points:livebirths (&gt; 37 weeks
      of gestation) and premature livebirths (&gt; 24, but &lt;37 weeks of gestation)

      Primary end-points: Pregnancy outcome: livebirths (&gt;37 weeks of gestation), premature
      livebirths (&gt; 24, but &lt;37 weeks of gestation) Secondary end-points: Bleeding complications,
      intrauterine growth retardation (&lt;-2SD), pre-eclampsia, abruptio placentae,

      Inclusion criteria: Three or more consecutive abortions of first trimester (ad h 12+6 wks) or
      two second trimester abortions (ad h 13 wks-23+6 wks) or one third trimester abortion (24
      weeks or more) with one first-second trimester abortions. Depending on the thrombophiliatest
      (tested before pregnancy) result the patients will included in one of the three sub-studies:

        1. HABENOX 1: those who have one thrombophiliatest positive: F V Leiden (heterozygote) or
           protein C or S deficiency, or anticardiolipin antibodies (low to moderate level),
           prothrombin gene mutation, or high level of F VIII.

        2. HABENOX 2: those with thrombophilia test negative

        3. HABENOX 3:those with &quot;high risk&quot; thrombophilia: positive combined thrombophilia, F V
           Leiden (homozygote), anticardiolipin antibodies (high level &gt;40) , lupusanticoagulant,
           or AT III deficiency.

      During next pregnancy the patient, with inclusion criteria fulfilled, will be asked to sign
      informed consent and she will be allocated into one of the three treatment groups. The
      treatment will be started before 7 weeks of gestation. At baseline and follow-up visits
      plasma, serum and 20 ml morning urine will be frozen (analysed later for antithrombin,
      protein S, C, APC ratio, PAI1, PAI2, U-PAR, D-dimer, thrombin-antithrombin (TAT) complex,
      CRP, TNFalpha(+ receptor), ICAM, VEGF(+receptor), urinary stabile metabolites of thromboxane
      and prostacyclin.

      Follow-up: US/Doppler + obstetric check-up at 8, 10, 14, 18, 24, 28, 32 and 36 weeks of
      gestation Ending: In the group of combined medication, tablets will be stopped at 36 weeks of
      gesta-tion. LMWH will be started in all patients after delivery and continued 6 weeks
      postpartum.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy outcome: livebirths (&gt;37 weeks of gestation), premature livebirths (&gt; 24, but &lt;37 weeks of gestation)</measure>
    <time_frame>gestational weeks &gt;37 and gestational weeks &gt; 24, but &lt;37</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications, intrauterine growth retardation (&lt;-2SD), pre-eclampsia, abruption placenta</measure>
    <time_frame>gestational weeks &gt; 37 and gestational weeks &gt;24, but &lt;37</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Habitual Abortion</condition>
  <arm_group>
    <arm_group_label>ASA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients received either Enoxaparine+placebo, Enoxaparine+ASA (Aspirin 100 mg) or ASA alone.ASA or placebo were blinded in the two first groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Klexane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clexane (enoxaparine) 40 mg sc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin and Enoxaparine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>ASA 100 mg once daily per os</description>
    <arm_group_label>ASA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Klexane</intervention_name>
    <description>Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3</description>
    <arm_group_label>Klexane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Klexane and ASA</intervention_name>
    <description>Klexane 40 mgx 1 sc and ASA 100 mg po</description>
    <arm_group_label>Aspirin and Enoxaparine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Habenox 1: Three or more consecutive abortions of first trimester (ad h 12+6 wks) or
             two second trimester abortions (ad h 13 wks-23+6 wks) or one third trimester abortion
             (24 weeks or more) with one first-second trimester abortions and one thrombophiliatest
             positive: F V Leiden (heterozygote) or protein C or S deficiency, or anticardiolipin
             antibodies (low to moderate level), prothrombin gene mutation, or high level of F
             VIII.

          -  HABENOX 2: The thrombophilic tests above are negative.

          -  HABENOX 3:positive combined thrombophilia, F V Leiden (homozygote), anticardiolipin
             antibodies (high level &gt;40) , lupusanticoagulant, or AT III deficiency.

        Exclusion Criteria:

          -  History of DVT or pulmonary embolism.

          -  Significant bleeding history.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veli-Matti Ulander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Hospital, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laure Morin-Papunen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katja Lampinen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kitty Bloemenkamp, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Hospital, Leiden, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janvier Visser, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Hospital, Leiden, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <last_update_submitted>August 13, 2009</last_update_submitted>
  <last_update_submitted_qc>August 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Risto Kaaja</name_title>
    <organization>Helsinki University Hospital</organization>
  </responsible_party>
  <keyword>Habitual abortion</keyword>
  <keyword>recurrent abortion</keyword>
  <keyword>hereditary and acquired</keyword>
  <keyword>thrombophilia</keyword>
  <keyword>preeclampsia</keyword>
  <keyword>premature birth</keyword>
  <keyword>miscarriage</keyword>
  <keyword>stillbirth</keyword>
  <keyword>LMWH (low molecular weigh heparin)</keyword>
  <keyword>ASA</keyword>
  <keyword>aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

